For security purposes
FOR SECURITY PURPOSES - because Internet Explorer is no longer supported by Microsoft, we suggest that you interact with our secure site through one of our supported browsers - Google Chrome, Firefox, or MS Edge. If you continue to use this website with Internet Explorer you do so at your own risk and you may encounter problems.
Documents
Meeting System Suitability for USP Abacavir and Lamivudine Tablets Assay
In this technical note, we report the separation of Lamivudine from its related chiral and diastereomeric impurities in Abacavir and Lamivudine tablets per the USP monograph using a Luna™ Omega 3 µm C18 column and a Kinetex™ 2.6 µm EVO C18 as alternative L1 columns to a XTERRA® 3.5 µm MS C18 column originally used to elucidate the monograph.

Meeting System Suitability for USP Abacavir and Lamivudine Tablets Assay

In this technical note, we report the separation of Lamivudine from its related chiral and diastereomeric impurities in Abacavir and Lamivudine tablets per the USP monograph using a Luna™ Omega 3 µm C18 column and a Kinetex™ 2.6 µm EVO C18 as alternative L1 columns to a XTERRA® 3.5 µm MS C18 column originally used to elucidate the monograph.
Document Type:
Technical Notes
Target Industries:
Separation Modes:
Reversed Phase

Can't view? Disable your browser's pop-up blocker.

Meeting System Suitability for USP Abacavir and Lamivudine Tablets Assay

In this technical note, we report the separation of Lamivudine from its related chiral and diastereomeric impurities in Abacavir and Lamivudine tablets per the USP monograph using a Luna™ Omega 3 µm C18 column and a Kinetex™ 2.6 µm EVO C18 as alternative L1 columns to a XTERRA® 3.5 µm MS C18 column originally used to elucidate the monograph.

Can't view? Disable your browser's pop-up blocker.